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Overnight
(reference) Ambulatory
Hazard Ratio (95%
CI)
p
value
no./total no.
(%)
no./total no.
(%)
Low ACEF
MACE 7/618 (1.1) 18/2214 (0.8) 0.716 (0.299 – 1.714) 0.453
Readmission 4/618 (0.6) 16/2214 (0.7)
All-cause
Death
1/618 (0.2) 0/2214 (0)
MI 4/618 (0.6) 3/2214 (0.1)
High ACEF
MACE 35/1098 (3.2) 22/1002 (2.2) 0.683 (0.401 – 1.165) 0.162
Readmission 14/1098 (1.3) 18/1002 (1.8)
All-cause
Death
20/1098 (1.8) 4/1002 (0.4)
MI 4/1098 (0.4) 1/1002 (0.1)
ACEF score: age/left ventricular ejection fraction 	 1 (if creatinine 2 mg/dl).
Conclusions: In this single-center registry, patients who underwent ambulatory PCI had
no worse outcomes than those who stayed at least one night, at high and low ACEF
scores.
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Background: The aim of this study was to evaluate the frequency, predictors and the
clinical outcome of stent thrombosis after DES implantation and bare metal stent (BMS)
implantation in Asian races.
Methods: A total of 14,577 consecutive patients who underwent successful DES
implantation (8,809 patients, 62% of the lesion with Sirolimus-eluting stent: SES, 38% of
the lesion with Paclitaxel-eluting stent: PES) and BMS implantation (5,768 patients) were
included in this study. We evaluate the frequency, predictor of stent thrombosis.
Results: At a mean follow-up of 78.529.9 months in DES and 81.826.4 months in
BMS. The cumulative incidence of stent thrombosis were subacute stent thrombosis
(SAT): 0.5% with DES and 0.6% with BMS, late stent thrombosis (LAST): 0.18% with
DES and 0.1% with BMS, very late stent thrombosis (VLAST): 0.18% per year with DES
and no BMS. Independent predictors of stent thrombosis are bifurcation lesion (OR1.90,
95% CI: 1.83 to 24.24, p0.01) and ejection fraction (OR0.90, 95% CI: 0.86 to 0.94,
p0.03). Only 0.2 % of the patients were died because of the myocardial infarction after
stent thrombosis in both groups.
Conclusions: The incidence of stent thrombosis in Asian races is relatively low (0.5 %
with DES and 0.6% with BMS of SAT, 0.18% increase per year with DES of late stent
thrombosis) at mean follow-up to 7 years. Particular attention will need to be directed to
this complication when the patients have bifurcation lesions or low ejection fraction.
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Background: Aims: To evaluate safety and effectiveness of the Elixir DESyneTM
Novolimus-Eluting Coronary Stent System (CSS) compared to the Endeavor
Zotarolimus-Eluting CSS through assessment of clinical, angiographic, and IVUS
endpoints.
Methods: 210 patients were randomized 2:1 either to the DESyne CSS loaded with 5mcg
per mm of stent length of Novolimus, a sirolimus metabolite, eluted via a durable
methacrylate polymer, or to the Endeavor CSS loaded with 10mcg per mm of stent length
of Zotarolimus eluted via a durable phosphoryl choline polymer. All patients were
analyzed for the primary endpoint of late lumen loss (LLL) assessed by QCA at 9 months.
All patients also underwent evaluation for secondary endpoints which included a
Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly
attributable to a non-intervention vessel, and clinically-indicated target lesion revascular-
ization (TLR); clinically-indicated Target Vessel Revascularization (TVR); and stent
thrombosis all evaluated at 1, 6, 9, and 12 months and annually through 5 years. Stents
were also assessed for angiographic endpoints at 9 months including: in-stent and
in-segment LLL. A subset of patients underwent IVUS evaluation including percent
neointimal obstruction at 9 months. The study met the non-inferiority endpoint and also
demonstrated superiority of the DESyne CSS as compared to control.
Results: Table 1 summarizes 9-month angiographic and IVUS results and clinical results
through 2 years which trend lower for the DESyne stent.
Table 1: 9-month Angiographic, IVUS and Clinical Results
DESyne Endeavor p-value
Angiographic Results
Baseline RVD (post-
procedure)
2.84 0.43 2.91 0.38 0.2
9-month angiographic/IVUS
In-stent LLL 0.11 0.32 0.63 0.42  0.001
% neointimal volume 4.5 5.1 20.9 11.3 0.001
Clinical Results
12-month DoCE (%) 4.3 7.0 0.51
Clinically-indicated TLR 1.4 5.6 0.18
24-month DoCE (%) 4.3 9.0 0.14
Clinically-indicated TLR 1.4 7.0 0.045
Conclusions: The study met the non-inferiority endpoint and also demonstrated
superiority of the DESyne CSS as compared to control. Clinical results through 3 years
and a review of angiographic and IVUS results will be presented.
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Background: Drug eluting stents (DES) have been shown to significantly decrease
restenosis with subsequent need for lesion and/or vessel revascularization when compared
with bare metal stents (BMS) in selected patient groups in both randomized controlled
trials and in observational registries. If their use in all-comers is also associated with a
survival benefit over a longer follow-up is controversial.
Methods: Retrospective analysis of the MIDAS registry for patients who underwent PCI
with BMS between January 1 1997-December 31 1998 (pre DES era, group 1; N
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19045), and patients who underwent PCI with BMS (group 2; N12559) and DES (group
3; N19346) between January 2003- December 31 2004 (DES era). All cause and
cardiovascular mortality was followed for all groups for 5 years.
Results: At 5 year follow up the unadjusted all- cause mortality was significantly higher
in group 2 (18.41%; p0.003) when compared with group 1 (14.01%) and group 3
(13.27%). The unadjusted cardiovascular mortality was significantly lower in group 3
(5.68% vs. 7.66% in gr 1 and 9.01% in gr 2; p0.0001). After adjusting for baseline
characteristics such as age, sex, race, diabetes, hypertension, renal disease, anemia, cancer,
cerebrovascular disease and left ventricular dysfunction there was a survival benefit
associated with DES ; the hazard ratios for total mortality and cardiovascular mortality
were 0.74 (95% CI 0.70 to 0.78; p0.0001) and 0.58 (95% CI 0.53 to 0.63; p0.0001)
respectively. For the patients from group 3 there was a significant survival benefit for
cardiovascular mortality (HR 0.83; CI 0.77-0.90; p0.0001) but not for total mortality
(HR 0.96; CI 0.91-1.02; p0.16) after adjustment for baseline characteristics.
Conclusions: In contemporary practice there appears to be a baseline selection bias in the
choice of stent type used during a PCI, with BMS being preferentially used in sicker
patients. This translates in a survival benefit in patients receiving DES, which may explain
the discrepancies in survival between stent registries and RCT.
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Background: It is now common practice to use coronary stents following PTCA to
restore blood flow in patients with CAD. The purpose of this study is to evaluate the
utilization of bare-metal stents (BMS) and drug-eluting stents (DES) and their revascu-
larization and mortality rates in the U.S. from 1997-2009.
Methods: The Medicare 5% LDS analytical files were queried to identify patients with
BMS and DES between 1997-2009 using ICD-9-CM. The subsequent rates of revascu-
larization and mortality were evaluated.
Results: A total of 88,000 BMS procedures were identified between 1997-2009 with a
revascularization rate of 31%. In addition, 68,300 DES procedures were identified from
2002-2009 with an overall revascularization rate of 19%. Within 2 years of FDA
approval, the DES dominated the stent market, accounting for 88.4% of all coronary stent
procedures in 2005. Due to DES safety concerns of late stent thrombosis, BMS utilization
increased steadily to 37% in 2007 with a simultaneous decrease in DES usage.
revascularization burden increased considerably from 8.2% in 1997 to 44.2% in 2009 for
BMS. The revascularization burden for DES increased at the same rate from 2006-2009.
The majority of patients undergoing stenting procedures were also diagnosed with
hypertension (75-85%) with revascularization rates higher among this population than
primary procedures. Over 60% of patients undergoing a DES stenting procedure (primary
or revascularization) are implanted with one stent while 27% are implanted with two
stents and less than 10% receive 3 or more stents. The same trend was observed for
patients undergoing primary or revascularization BMS procedures. Ten-year Kaplan Meir
mortality rates were also assessed among the DES and BMS patient populations. The
average hospitalization charges for primary DES procedures was $64,000, whereas the
average charges for BMS procedures were $10,000-23,000 lower than DES procedures.
Conclusions: Temporal trends showed that concerns about late-stent thrombosis with use
of DES led to a sharp decline in utilization. Analysis of mortality and revascularization
following BMS and DES procedures provided information about the comparative safety
and effectiveness of these procedures.
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Background: Acute cerebrovascular episode (CVA) following percutaneous coronary
intervention (PCI) is a rare but devastating complication. We sought to determine the
incidence and predictors of stroke following PCI in United States.
Methods: The Nationwide Inpatient Sample (NIS) database was used to identify all
patients who developed acute CVA following PCI between January and December 2009.
Risk adjusted logistic regression was performed to identify independent predictors of
acute stroke following PCI.
Results: Of the 444,326 patients who underwent PCI, 437 (0.1%) acute strokes were
identified. The in-hospital mortality rate in patients who developed stroke was signifi-
cantly higher than in control group (2.3% vs. 0.6%, p  0.01). Independent predictors of
stroke following PCI were history of drug abuse (OR 7.2, 95% CI {4.5 – 11.4}, p0.01),
valvular heart disease (OR 3.2, 95% CI {1.6 – 6.7}, p  0.01), age 65 (OR 2.9, 95%
CI {2.3 – 3.7}, p0.01), diabetes with complications (OR 2.0, 95% CI {1.4 – 2.7}, p
0.01), female sex (OR 1.6, 95% CI {1.3 – 2.0}, p  0.01), history of coronary artery
bypass grafting (OR 1.6, 95% CI {1.2 – 2.1}, p  0.01) and history of myocardial
infarction (OR 1.5, 95% CI {1.2 – 1.9}, p  0.01).
Conclusions: In this observational study we found that risk of stroke following PCI is
low, whereas the in-hospital mortality associated with this complication is high. The
independent predictors of stroke complication include history of drug abuse, valvular
heart disease, advanced age, diabetes with complications, prior CABG or MI.
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Background: Endothelial dysfunction of coronary artery has been reported in patients
following the first generation drug eluting stent (DES) implantation. However, the
incidence and clinical relevance of the second generation DES-induced endothelial
dysfunction have not been fully investigated. The aim of this study was to estimate the
incidence and clinical relevance of endothelial dysfunction after implantation of
everolimus-eluting stent (EES).
Methods: Since June 2006 until August 2011, the present study enrolled 757 patients
who were treated solely with DES for de novo lesions, from our prospective institutional
database. The patients (279 patients with sirolimus-eluting stent (SES), 210 patients with
paclitaxel-eluting stent (PES), and 268 patients with EES) were requested to undergo
8-month follow-up angiography. Endothelial function was evaluated, in case the patients
had angina symptom and/or positive exercise electrocardiogram test without in-stent
restenosis at the time of follow-up angiography by infusion of incremental acetylcholine
and isosorbide dinitrate into the coronary artery. Vascular responses were quantitatively
measured in segments proximal, distal, proximal reference and distal reference to DES
location. Endothelial dysfunction was defined as abnormal vasoconstriction of  3%
mean vessel diameter changes.
Results: Follow-up angiography was performed in 624 patients (82.4%)of the 757
patients. There were 59 patients (7.8%) who met the inclusion criteria for endothelial
function test, 25 patients (8.9%) with SES, 15 patients (7.1%) with PES, 19 patients
(7.1%) with EES. In all the 3 groups significant vasoconstriction after acetylcholine
infusion was observed in segments distal to stents compared to baseline(p0.05).
Vasodilation in response to isosorbide dinitrate infusion was also observed. Endothelial
dysfunction was quantitatively assessed in all the 59 patients at distal segments to DES.
No significant differences were observed in percent diameter changes from baseline
among the groups.
Conclusions: Clinically relevant endothelial dysfunction following EES implantation
seems to be present in approximately 7%, which is similar to the first generation DES
implantation.
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Background: The level of appropriateness of PCI in the appropriate use criteria (AUC)
are based on degree of symptoms and abnormalities on stress testing. Using these criteria,
PCI in patients with asymptomatic CAD (ACAD) is often labeled as inappropriate.
However, whether this is due to increased harm or perceived decreased benefit, is not
clear. Furthermore, many PCI’s performed for other instances not related to angina (i.e.
CHF, arrhythmias) and are not included as reasons for PCI in the AUC. Therefore, we
sought to investigate the outcomes of patients undergoing PCI for asymptomatic CAD
compared to those with stable angina (SA).
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